Active Biotech AB (publ) (ACTI.ST)
SEK 0.07
(-1.67%)
SEK 0.07
(-1.67%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | -2500.00 SEK | 0.0% |
| 2022 | - SEK | 0.0% |
| 2021 | - SEK | 0.0% |
| 2020 | - SEK | 0.0% |
| 2019 | - SEK | 100.0% |
| 2018 | -2.03 Million SEK | 28.89% |
| 2017 | -2.86 Million SEK | -19630136986301470.0% |
| 2016 | - SEK | 100.0% |
| 2015 | -13.92 Million SEK | -2914.07% |
| 2014 | -462 Thousand SEK | 82.91% |
| 2013 | -2.7 Million SEK | -2960.36% |
| 2012 | -88.32 Thousand SEK | 0.0% |
| 2011 | - SEK | 0.0% |
| 2010 | - SEK | 0.0% |
| 2009 | - SEK | 0.0% |
| 2008 | - SEK | 0.0% |
| 2007 | - SEK | 0.0% |
| 2006 | - SEK | 0.0% |
| 2005 | - SEK | 0.0% |
| 2004 | - SEK | 0.0% |
| 2003 | - SEK | 0.0% |
| 2002 | - SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | - SEK | 100.0% |
| 2024 Q3 | -4.4 Million SEK | 100.0% |
| 2024 Q2 | -3.6 Million SEK | 0.0% |
| 2023 FY | -2500.00 SEK | 0.0% |
| 2023 Q1 | -2800.00 SEK | 0.0% |
| 2023 Q3 | -3100.00 SEK | -6.9% |
| 2023 Q2 | -2900.00 SEK | -3.57% |
| 2023 Q4 | -2500.00 SEK | 19.35% |
| 2022 Q4 | - SEK | 100.0% |
| 2022 Q2 | -3.7 Million SEK | 0.0% |
| 2022 Q1 | - SEK | 0.0% |
| 2022 FY | - SEK | 0.0% |
| 2022 Q3 | -3.8 Million SEK | -2.7% |
| 2021 Q1 | -3.5 Million SEK | -1132.39% |
| 2021 Q2 | -3.3 Million SEK | 5.71% |
| 2021 Q4 | - SEK | 100.0% |
| 2021 Q3 | -3.4 Million SEK | -3.03% |
| 2021 FY | - SEK | 0.0% |
| 2020 Q4 | -284 Thousand SEK | 0.0% |
| 2020 FY | - SEK | 0.0% |
| 2020 Q1 | -3.4 Million SEK | -305.73% |
| 2020 Q2 | - SEK | 100.0% |
| 2020 Q3 | - SEK | -100.0% |
| 2019 Q2 | -5.7 Million SEK | -102.1% |
| 2019 Q4 | -838 Thousand SEK | 84.76% |
| 2019 FY | - SEK | 100.0% |
| 2019 Q1 | 271.8 Million SEK | 129528.57% |
| 2019 Q3 | -5.5 Million SEK | 3.51% |
| 2018 Q2 | 1000.00 SEK | 0.0% |
| 2018 Q1 | 1000.00 SEK | 120.0% |
| 2018 Q3 | -4.2 Million SEK | -420100.0% |
| 2018 Q4 | -210 Thousand SEK | 95.0% |
| 2018 FY | -2.03 Million SEK | 28.89% |
| 2017 Q2 | -7.4 Million SEK | -1.37% |
| 2017 Q4 | -5000.00 SEK | -600.0% |
| 2017 FY | -2.86 Million SEK | -19630136986301470.0% |
| 2017 Q1 | -7.3 Million SEK | -50000000000000100.0% |
| 2017 Q3 | 1000.00 SEK | 100.01% |
| 2016 Q1 | -1.9 Million SEK | -259.17% |
| 2016 FY | - SEK | 100.0% |
| 2016 Q3 | -5.9 Million SEK | 21.33% |
| 2016 Q2 | -7.5 Million SEK | -294.74% |
| 2016 Q4 | - SEK | 100.0% |
| 2015 FY | -13.92 Million SEK | -2914.07% |
| 2015 Q4 | -529 Thousand SEK | 94.19% |
| 2015 Q3 | -9.1 Million SEK | -31271477663230140.0% |
| 2015 Q2 | - SEK | 0.0% |
| 2015 Q1 | - SEK | 100.0% |
| 2014 Q2 | - SEK | 0.0% |
| 2014 Q4 | -462 Thousand SEK | 93.4% |
| 2014 Q3 | -7 Million SEK | 0.0% |
| 2014 Q1 | - SEK | 100.0% |
| 2014 FY | -462 Thousand SEK | 82.91% |
| 2013 Q4 | -2.7 Million SEK | 97.62% |
| 2013 Q3 | -113.8 Million SEK | 0.0% |
| 2013 FY | -2.7 Million SEK | -2960.36% |
| 2013 Q1 | - SEK | 100.0% |
| 2013 Q2 | - SEK | -100.0% |
| 2012 Q4 | -88.32 Thousand SEK | -741.17% |
| 2012 Q1 | - SEK | 0.0% |
| 2012 Q2 | - SEK | 0.0% |
| 2012 FY | -88.32 Thousand SEK | 0.0% |
| 2012 Q3 | -10.5 Thousand SEK | 0.0% |
| 2011 Q1 | - SEK | 0.0% |
| 2011 Q2 | - SEK | 0.0% |
| 2011 Q3 | - SEK | 0.0% |
| 2011 Q4 | - SEK | 0.0% |
| 2011 FY | - SEK | 0.0% |
| 2010 Q4 | - SEK | 0.0% |
| 2010 FY | - SEK | 0.0% |
| 2010 Q2 | - SEK | 0.0% |
| 2010 Q1 | - SEK | 0.0% |
| 2010 Q3 | - SEK | 0.0% |
| 2009 FY | - SEK | 0.0% |
| 2009 Q4 | - SEK | 0.0% |
| 2008 FY | - SEK | 0.0% |
| 2007 FY | - SEK | 0.0% |
| 2006 FY | - SEK | 0.0% |
| 2005 FY | - SEK | 0.0% |
| 2004 FY | - SEK | 0.0% |
| 2003 FY | - SEK | 0.0% |
| 2002 FY | - SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Alzinova AB (publ) | -3.27 Million SEK | 99.924% |
| Amniotics AB (publ) | 534 Thousand SEK | 100.468% |
| Asarina Pharma AB (publ) | - SEK | Infinity% |
| BioArctic AB (publ) | - SEK | Infinity% |
| Calliditas Therapeutics AB (publ) | 20.42 Million SEK | 100.012% |
| Genovis AB (publ.) | 14.9 Million SEK | 100.017% |
| LIDDS AB (publ) | - SEK | Infinity% |
| Magle Chemoswed Holding AB (publ) | 35.22 Million SEK | 100.007% |
| OncoZenge AB (publ) | -862.99 Thousand SEK | 99.71% |
| Saniona AB (publ) | 1.00 SEK | 250100.0% |
| Simris Alg AB (publ) | 1.09 Million SEK | 100.229% |
| Vicore Pharma Holding AB (publ) | - SEK | Infinity% |
| AcouSort AB (publ) | 2.08 Million SEK | 100.12% |
| Camurus AB (publ) | 100.95 Million SEK | 100.002% |
| Cantargia AB (publ) | - SEK | Infinity% |
| Scandinavian ChemoTech AB (publ) | 4.03 Million SEK | 100.062% |
| Guard Therapeutics International AB (publ) | -1486.00 SEK | -68.237% |
| Mendus AB (publ) | - SEK | Infinity% |
| Kancera AB (publ) | -1950.00 SEK | -28.205% |
| Karolinska Development AB (publ) | - SEK | Infinity% |
| Lipum AB (publ) | - SEK | Infinity% |
| Lipigon Pharmaceuticals AB (publ) | -1.62 Million SEK | 99.846% |
| NextCell Pharma AB | 545.23 Thousand SEK | 100.459% |
| Xbrane Biopharma AB (publ) | 106.85 Million SEK | 100.002% |
| Xintela AB (publ) | 398 Thousand SEK | 100.628% |
| Ziccum AB (publ) | -4.18 Million SEK | 99.94% |
| Elicera Therapeutics AB (publ) | -446.98 Thousand SEK | 99.441% |
| Modus Therapeutics Holding AB (publ) | - SEK | Infinity% |
| Isofol Medical AB (publ) | - SEK | Infinity% |
| Xspray Pharma AB (publ) | 43.78 Million SEK | 100.006% |
| CombiGene AB (publ) | -1.79 Million SEK | 99.861% |
| Diamyd Medical AB (publ) | 24.05 Million SEK | 100.01% |
| Intervacc AB (publ) | 10.48 Million SEK | 100.024% |
| Alligator Bioscience AB (publ) | 2.00 SEK | 125100.0% |
| Sprint Bioscience AB (publ) | -7.13 Million SEK | 99.965% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | - SEK | Infinity% |
| Corline Biomedical AB | -3.85 Million SEK | 99.935% |
| IRLAB Therapeutics AB (publ) | 1000.00 SEK | 350.0% |
| Bio-Works Technologies AB (publ) | 9.06 Million SEK | 100.028% |
| Aptahem AB (publ) | - SEK | Infinity% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | Infinity% |
| Fluicell AB (publ) | 3.15 Million SEK | 100.079% |
| Biovica International AB (publ) | 2.19 Million SEK | 100.114% |
| Spago Nanomedical AB (publ) | 1.00 SEK | 250100.0% |
| Abliva AB (publ) | - SEK | Infinity% |
| Egetis Therapeutics AB (publ) | 700 Thousand SEK | 100.357% |
| 2cureX AB (publ) | -1000.00 SEK | -150.0% |
| I-Tech AB | 4.28 Million SEK | 100.058% |
| Hansa Biopharma AB (publ) | 9.79 Million SEK | 100.026% |
| Cyxone AB (publ) | - SEK | Infinity% |
| ExpreS2ion Biotech Holding AB (publ) | - SEK | Infinity% |
| Biosergen AB | -4.92 Million SEK | 99.949% |
| Nanologica AB (publ) | 2.97 Million SEK | 100.084% |
| SynAct Pharma AB | - SEK | Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | Infinity% |
| BioInvent International AB (publ) | 11.84 Million SEK | 100.021% |
| Stayble Therapeutics AB (publ) | -321.14 Thousand SEK | 99.222% |
| Oncopeptides AB (publ) | 2.42 Million SEK | 100.103% |
| Pila Pharma AB (publ) | 1.00 SEK | 250100.0% |
| Ascelia Pharma AB (publ) | - SEK | Infinity% |
| Diagonal Bio AB (publ) | 1.02 Million SEK | 100.243% |